Mediastinal Bulky Tumour in Hodgkin’s Disease and Prognostic Value of Positron Emission Tomography in the Evaluation of Post-Treatment Residual Masses
- 1 November 2004
- journal article
- Published by S. Karger AG in Acta Haematologica
- Vol. 112 (4) , 194-199
- https://doi.org/10.1159/000081271
Abstract
Among the 193 patients (82 female, 111 male) treated primarily for Hodgkin's disease at our clinic between 1990 and 2001 and followed up until 2003, 42 (22%) had mediastinal bulky tumours (MBTs) by the Cotswolds criteria. The rate of MBT diagnosis was significantly greater in the early stage of the disease, these patients were younger and--in contrast to the other group--they all received combined therapy. No significant differences were found in the overall and relapse-free survival rate in the two groups, but relapse and death rates were lower in the patients with bulky tumours. Of the total number of patients, 27 underwent a total of 31 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) examinations, mainly for the evaluation of post-treatment residual mass viability. In the 12 positive cases, the majority of patients received further therapy. During the mean follow-up time of 58 months (range 5-98 months) after obtaining negative results, progression of the disease was found in 2 cases 14 and 23 months later, respectively. Based on our results, we conclude that FDG-PET examinations show a good correlation with clinical follow-up results.Keywords
This publication has 25 references indexed in Scilit:
- Primary systemic treatment of advanced Hodgkin’s disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-upAnnals of Oncology, 2003
- An elevated serum beta‐2‐microglobulin level is an adverse prognostic factor for overall survival in patients with early‐stage Hodgkin diseaseCancer, 2002
- Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical TrialJournal of Clinical Oncology, 2002
- Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphomaBritish Journal of Haematology, 2001
- Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin diseaseBlood, 2001
- Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible?European Journal of Nuclear Medicine and Molecular Imaging, 1999
- ABVD and Radiation Therapy as First-Line Treatment in Advanced Hodgkin's DiseaseLeukemia & Lymphoma, 1999
- Massive Mediastinal Involvement in Stage I-II Hodgkin's Disease: Response to Combined Modality TreatmentLeukemia & Lymphoma, 1992
- The prognostic significance of large mediastinal masses in the treatment of Hodgkin's disease. The experience of the institut gustave‐roussyHematological Oncology, 1984
- Prognostic Significance of Large Mediastinal Involvement in Hodgkin's DiseaseScandinavian Journal of Haematology, 1983